TherapeuticsMD, Inc.
Attention: Valerie Ahmuty
Vice President, Regulatory Affairs
951 Yamato Road, Suite 220
Boca Raton, FL 33431

Dear Ms. Ahmuty:

Please refer to your supplemental new drug applications (sNDAs) dated and received January 9, and November 27, 2019, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Bijuva (estradiol and progesterone) capsules, for oral use.

We also acknowledge receipt of your S-003 amendment dated September 16, 2020, which constituted a complete response to our May 27, 2020, action letter.

These Prior Approval sNDAs provide for changes as requested in the FDA Prior Approval Supplement Request letter dated December 10, 2018, and revised language to Section 11 DESCRIPTION that was deemed acceptable in the FDA Meeting Request Written Responses letter dated September 4, 2020, as well as annual reportable changes.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

Reference ID: 4814984
Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As. The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim Shiley, R.N., B.S.N., Regulatory Project Manager, at (301) 796-2117.

Sincerely,

{See appended electronic signature page}

Christine P. Nguyen, M.D.
Director
Division of Urology, Obstetrics, and Gynecology
Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Medicine
Center for Drug Evaluation and Research

**ENCLOSURES:**
- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

---

2. We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm)

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/
CHRISTINE P NGUYEN
06/22/2021 02:33:47 PM